Do you qualify for tirzepatide? BMI and eligibility explained

If you have spent years cycling through diets and still feel like food occupies more mental real estate than it should, you are not imagining things and you are not failing. Research on metabolic adaptation — including the NIH's long-term follow-up of 'Biggest Loser' contestants (Fothergill et al., 2016) — shows that sustained caloric restriction slows resting metabolism and drives hunger hormones upward, making regain nearly inevitable through willpower alone. Tirzepatide works at the hormonal level to interrupt that cycle. But it is not for everyone, and knowing exactly who qualifies is the first honest step.

What the clinical eligibility criteria actually say

The FDA-approved brand-name products Zepbound (for chronic weight management) and Mounjaro (for type 2 diabetes) established the benchmarks that licensed prescribers now use when evaluating any tirzepatide prescription, including prescriptions for compounded tirzepatide prepared by a US-licensed compounding pharmacy. Those benchmarks come directly from the SURMOUNT clinical trial program.

Zepbound's FDA-approved labeling specifies two distinct eligibility tracks:

• BMI of 30 or higher — classified as obesity — regardless of whether any other health conditions are present.
• BMI of 27 or higher — classified as overweight — plus at least one weight-related health condition such as high blood pressure, type 2 diabetes, obstructive sleep apnea, or high cholesterol.

A StaveMD provider uses these same evidence-based thresholds when reviewing your intake. They are not arbitrary lines drawn by an insurance company. They reflect the populations studied in SURMOUNT-1, where participants had a mean BMI of approximately 38 and where the tirzepatide molecule — at the 15 mg dose — produced a mean body-weight loss of up to 20.9% over 72 weeks (Jastreboff et al., NEJM 2022; not StaveMD patient data). The criteria exist to identify the people most likely to benefit and to exclude those for whom the risk-benefit calculation is different.

How to estimate your BMI — and why it is only part of the picture

BMI is calculated by dividing your weight in kilograms by your height in meters squared. If you prefer pounds and inches, the formula is: (weight in pounds / height in inches squared) x 703. A quick online calculator takes about ten seconds. You do not need a lab value or a doctor's visit to get a number.

That said, BMI is a screening tool, not a complete health assessment. It does not distinguish muscle from fat, does not account for fat distribution, and does not capture metabolic markers. Someone with a BMI of 28 and hypertension, insulin resistance, or sleep apnea carries meaningfully different health risk than someone with a BMI of 28 and no related conditions. That is exactly why the second eligibility track exists — and why weight-related comorbidities are not a technicality. They are a legitimate clinical signal.

Common weight-related conditions that can qualify you under the BMI 27+ track include:

• Hypertension (high blood pressure), even if currently managed with medication.
• Type 2 diabetes or prediabetes (elevated fasting glucose or HbA1c).
• Obstructive sleep apnea, diagnosed or strongly suspected.
• Dyslipidemia — elevated triglycerides, low HDL, or high LDL.
• Cardiovascular disease or a documented history of it.

Who is not a good candidate — what disqualifies you

Honest eligibility information runs in both directions. There are contraindications to tirzepatide that a provider will screen for, and being upfront about them during your intake protects you.

• Personal or family history of medullary thyroid carcinoma (MTC) — tirzepatide carries a boxed warning for thyroid C-cell tumors based on animal studies; the risk in humans is not fully established, but prescribers take it seriously.
• Personal or family history of Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), which is associated with MTC.
• Current pregnancy or plans to become pregnant — weight-loss medication is not appropriate during pregnancy.
• Severe gastroparesis or certain other gastrointestinal conditions that could be worsened by GLP-1 receptor agonism.
• Prior serious hypersensitivity reaction to tirzepatide or any component of the formulation.
• Certain pancreatic conditions — a history of pancreatitis warrants careful provider evaluation.

This list is not exhaustive, and individual clinical judgment matters. A StaveMD provider will review your full health history, not just run your BMI through a spreadsheet.

What to expect from the evidence — and what it cannot promise you

The tirzepatide molecule has one of the strongest weight-loss efficacy profiles in the GLP-1 class. In the head-to-head SURMOUNT-5 trial, tirzepatide produced approximately 20.2% mean body-weight loss compared to 13.7% for semaglutide — again, these are tirzepatide molecule clinical-trial findings, not StaveMD patient data. That difference matters if you have been on semaglutide and found it insufficient.

Individual results, however, vary in ways the averages do not show. Some people lose significantly more than 20%; some lose less. Dose tolerability, starting weight, metabolic history, and adherence all shape outcomes. Side effects — most commonly nausea, constipation, diarrhea, and reduced appetite — are real and can be pronounced during dose escalation. Most people find them manageable with a slow titration schedule, but some do not tolerate the medication at all.

Compounded tirzepatide is prepared by a US-licensed compounding pharmacy under a valid prescription. It is not an FDA-approved finished drug product. It is not manufactured or compounded by StaveMD. Because compounded medications are not FDA-approved, they have not undergone the same pre-market review as Zepbound or Mounjaro. That transparency is worth stating plainly: compounding is a legal and established pharmaceutical practice, but it is a different regulatory category, and you deserve to know that.

What the clinical data does tell you is that the mechanism is sound, the molecule has been rigorously studied, and the persistent mental chatter about food — what many patients call 'food noise' — is one of the most consistently reported things that quiets on tirzepatide. That is not a marketing claim. It reflects how dual GIP and GLP-1 receptor agonism affects appetite signaling in the brain. Your hunger was never purely a matter of discipline.

How StaveMD's eligibility process works

StaveMD operates as a telehealth platform that connects you with US-licensed providers. There is no insurance required. You complete a two-minute intake that captures your height, weight, health history, current medications, and goals. A provider reviews your intake — not an algorithm — and determines whether a prescription for compounded tirzepatide is clinically appropriate for you.

If you qualify, the prescription is sent to a US-licensed compounding pharmacy. If you do not qualify or if a provider identifies a concern, you are told why — directly, without a runaround. Pricing is disclosed before you commit. There are no hidden fees layered in after you have already handed over a credit card number.

The short version of qualification: BMI 30 or higher, or BMI 27 or higher with a weight-related health condition, and none of the contraindications listed above. If you are close to the line or unsure about a condition, the intake is the right place to start — not a self-diagnosis spiral.